Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Priscilla Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergan Aesthetics, an AbbVie Company, Irvine, California, USA. Hauptthemen laut MEDLINE: Cosmetics, Skin Aging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie Company.
Abstract (Originalsprache)
Background
Growth factor preparations have demonstrated effectiveness in reversing age‐related changes in facial skin. TNS® Advanced+ Serum (TNS A+ Serum; SkinMedica®, Allergan Aesthetics, an AbbVie Company) and TNS Advanced+ Pro‐Infusion Serum for DiamondGlow® (DG‐TNS A+; Allergan Aesthetics) combine growth factor technology with active botanical ingredients to target signs of skin aging.
Aims
This prospective clinical study evaluated the effectiveness and tolerability of biweekly facial hydradermabrasion (DiamondGlow [DG]; Allergan Aesthetics) plus DG‐TNS A+ combined with at‐home topical TNS A+ Serum.
Methods
Females aged 25–65 years with mild to severe facial photodamage received 6 biweekly DG plus DG‐TNS A+ in‐office treatments with at‐home twice‐daily TNS A+ Serum for 12 weeks. Investigator‐assessed clinical grading of multiple skin attributes, subject self‐assessments, instrumentation measurements, and clinical grading of irritation parameters (0–3, none to severe) were conducted at Visit 1, Day 3, and biweekly from Weeks 2–12.
Results
Twenty‐nine women (Fitzpatrick skin types II–VI; 52% White, 41% African American) were enrolled. Immediate significant improvements after 1 DG plus DG‐TNS A+ treatment were observed for fine lines/wrinkles, skin smoothness (visual and tactile), radiance, and hydration (all p ≤ 0.004). From Weeks 6–12, all investigator‐assessed parameters showed significant improvements versus baseline (all p ≤ 0.002 at Week 12). Mean tolerability scores were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
- SGS Stephens Inc., Richardson, Texas, USA.
ORCID-Profile: Priscilla Huang
Förderung
- Allergan Aesthetics, an AbbVie Company
Zitieren
APA
Huang, P., Mehta, R., Emmerich, T., Jiang, L. I., & Makino, E. (2024). Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16229
Vancouver
Huang P, Mehta R, Emmerich T, Jiang LI, Makino E. Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16229
BibTeX
@article{Huang2024,
author = {Huang, Priscilla and Mehta, Rahul and Emmerich, Tanja and Jiang, Lily I and Makino, Elizabeth},
title = {Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16229}
}
EUVIMED